Syndax Pharmaceuticals (SNDX) Profit After Tax: 2015-2024
Historic Profit After Tax for Syndax Pharmaceuticals (SNDX) over the last 10 years, with Dec 2024 value amounting to -$318.8 million.
- Syndax Pharmaceuticals' Profit After Tax fell 45.88% to -$20.4 million in Q4 2020 from the same period last year, while for Dec 2020 it was -$73.2 million, marking a year-over-year decrease of 30.53%. This contributed to the annual value of -$318.8 million for FY2024, which is 52.25% down from last year.
- Per Syndax Pharmaceuticals' latest filing, its Profit After Tax stood at -$318.8 million for FY2024, which was down 52.25% from -$209.4 million recorded in FY2023.
- Syndax Pharmaceuticals' 5-year Profit After Tax high stood at $24.9 million for FY2021, and its period low was -$318.8 million during FY2024.
- Moreover, its 3-year median value for Profit After Tax was -$209.4 million (2023), whereas its average is -$225.8 million.
- In the last 5 years, Syndax Pharmaceuticals' Profit After Tax spiked by 134.07% in 2021 and then crashed by 699.13% in 2022.
- Yearly analysis of 5 years shows Syndax Pharmaceuticals' Profit After Tax stood at -$73.2 million in 2020, then soared by 134.07% to $24.9 million in 2021, then crashed by 699.13% to -$149.3 million in 2022, then tumbled by 40.19% to -$209.4 million in 2023, then plummeted by 52.25% to -$318.8 million in 2024.